Interview with Jean-Philippe Duc, Country Manager, Amgen Czech Republic
Mr. Duc, you first worked in the Czech Republic in 1997, as an Oncology Business Unit manager for Pierre Fabre. The ‘90s in this country have been described to us…
Address: Amgen Ltd. Klimentská 46 110 02 Prague 1,Czech Republic
Tel: +420 221 773 500
Web: http://www.amgen.cz/
Amgen commenced operations in Central and Eastern Europe on 1 May 2004, when the first eight countries of the region became members of the EU. Since then, Amgen’s Central European activities have constantly expanded. Among the company’s focus markets in the region are the Czech Republic, Poland, Hungary, Slovakia and Romania. Amgen is also active in Lithuania, Latvia, Estonia, Slovenia, Bulgaria.Amgen entered the Czech market in May 2004.The company is headquartered in Prague, but its team covers the whole territory of the Republic. At present, the Czech branch has over 60 employees.
Amgen discovers, develops, manufactures, and delivers innovative human therapeutics. A leader in biotechnology since 1980, Amgen was one of the first companies to realize the new science’s promise by bringing safe, effective medicines from lab, to manufacturing plant, to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, bone disease, and other serious illnesses.
Mr. Duc, you first worked in the Czech Republic in 1997, as an Oncology Business Unit manager for Pierre Fabre. The ‘90s in this country have been described to us…
Mr. Dvořáček, in 2010, the AIFP commissioned a study on the economic footprint of the innovative pharmaceutical industry in the Czech Republic. Can you begin by expounding the results of…
Mr. Kotek, can you please begin by introducing us to the SVOPL and telling us what the mission is here in the Czech Republic? We are a relatively new Association…
See our Cookie Privacy Policy Here
